Oculus Innovative Sciences, Inc. OCLS announced today that it has entered into a definitive agreement with a single life science-focused institutional investor for the purchase of a combination of ...

Oculus Innovative Sciences has entered into an agreement with OroScience granting Oroscience exclusive rights to market Microcyn-based oral products in the U.S., Canada, and Europe in exchange for ...

The company lowered the terms for its IPO, initially slated for the week of December 18. Please refer to the original IPO summary for more information about the company.

Co announces it has entered into an exclusive licensing agreement with the Drug Enhancement Company of America, under which Oculus licensed rights to its Microcyn Technology for use in an over- ...